Get the Stockscreener App
2.00
4.29%
-0.10
Autolus Therapeutics Plc Adr stock is traded at $2.00, with a volume of 1.15M.
It is down -4.29% in the last 24 hours and down -20.24% over the past month.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
See More
Previous Close:
$2.10
Open:
$2.1
24h Volume:
1.15M
Relative Volume:
0.67
Market Cap:
$558.86M
Revenue:
-
Net Income/Loss:
$-208.38M
P/E Ratio:
-1.6667
EPS:
-1.2
Net Cash Flow:
$-156.57M
1W Performance:
-9.05%
1M Performance:
-20.24%
6M Performance:
-50.00%
1Y Performance:
-68.20%
1-Day Range:
$1.99
$2.13
1-Week Range:
$1.99
$2.23
52-Week Range:
$1.99
$7.37
Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile
Name
Autolus Therapeutics Plc Adr
Sector
Industry
Phone
44 20 3829 6230
Address
THE MEDIAWORKS, LONDON
Compare AUTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUTL
Autolus Therapeutics Plc Adr
|
2.00 | 558.86M | 0 | -208.38M | -156.57M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.85 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.27 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.13 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.65 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.63 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Upgrade | Goldman | Neutral → Buy |
| Nov-15-24 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Mar-27-23 | Resumed | Wells Fargo | Overweight |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Jun-14-21 | Upgrade | Jefferies | Hold → Buy |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | JP Morgan | Overweight |
| Jul-22-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Sep-23-19 | Initiated | Needham | Buy |
| May-17-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-24-18 | Initiated | H.C. Wainwright | Buy |
View All
Autolus Therapeutics Plc Adr Stock (AUTL) Latest News
There is no doubt that Nurix Therapeutics Inc (NRIX) ticks all the boxes. - SETE News
Enovis Corp (ENOV) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Check Out TC BioPharm (Holdings) plc ADR (TCBP)’s Trade Data Rather Than the Analysts’ Views - SETE News
You might want to take a look at Autolus Therapeutics plc ADR (AUTL) now - SETE News
Clean Energy Fuels Corp (CLNE)’s stock rises to 3.45 per share - US Post News
Adc Therapeutics SA (ADCT) stock analysis: A comprehensive overview - US Post News
GH Research PLC (GHRS) stock: A year of ups and downs - US Post News
Calumet Inc (CLMT)’s stock price range in the last year - US Post News
A closer look at Autolus Therapeutics plc ADR (AUTL)’s stock price trends - US Post News
Quarterly Snapshot: Quick and Current Ratios for Autolus Therapeutics plc ADR (AUTL) - The Dwinnex
Balance Sheet Insights: Edison International (EIX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Selling Your Standard Lithium Ltd (AMEX: SLI) Stock? Here’s What You Need To Know - Stocks Register
Autolus presents new data on CAR-T therapy cost benefits - Investing.com
Autolus' AUCATZYL Shows Superior Cost-Effectiveness and 84% Deep Remission Rate in Latest Data - StockTitan
A Stock Analysis Of Autolus Therapeutics plc ADR’s (AUTL) - Stocks Register
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 - GlobeNewswire Inc.
MicroAlgo Inc’s (MLGO) -2.91% Drop Is A Reason To Reconsider. - Stocks Register
Aspen Aerogels Inc (ASPN) Strikes $14.34: The Risk Seems Worthwhile At This Price - Stocks Register
Autolus reports high response in leukemia study - Investing.com India
CommScope Holding Company Inc (COMM) Is A Good Investment At Current Valuations - Stocks Register
Autolus Therapeutics plc ADR (AUTL) Has A Gold Mine On Its Hands - Stocks Register
These Numbers Prove Just How Vibrant The Ocugen Inc (NASDAQ: OCGN) Stock Has Been - Stocks Register
Autolus stock upgraded as obe-cel approval drives optimism for commercial potential - Investing.com
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - Barchart
Does MP Materials Corporation (NYSE: MP) Still Need To Convince Analysts? - Stocks Register
Hafnia Ltd (NYSE: HAFN) Drops -3.00%, Turning Investors Away - Stocks Register
Autolus Therapeutics (AUTL): High-Growth UK Stock in Cancer Therapy - Yahoo Finance
Why Autolus Therapeutics plc (AUTL) is the Penny Stock with the Biggest Upside Potential According to Analysts - Yahoo Finance
PDD Holdings Inc ADR (NASDAQ: PDD) Has Been Trading Down. What Are The Prospects For The Future? - Stocks Register
What Do Wall Street Analysts Think About Moderna Inc (NASDAQ: MRNA) Stock? - Stocks Register
Before You Invest, Make Sure You Check This Autolus Therapeutics plc ADR (NASDAQ: AUTL) Analysis - Stocks Register
Autolus Therapeutics plc ADR (AUTL)’s stock rises to 4.14 per share - US Post News
Autolus Therapeutics plc ADR: -44.83% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle
A better buy-in window may exist right now for Autolus Therapeutics plc ADR (AUTL) - SETE News
Upward Trajectory: Autolus Therapeutics plc ADR (AUTL) Posts a Slidee, Closing at 3.98 - The Dwinnex
Autolus Therapeutics plc ADR (AUTL) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Are Smart Investors Making the Right Decision? Autolus Therapeutics plc ADR (AUTL) - SETE News
Autolus Therapeutics plc ADR (AUTL) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Autolus Therapeutics plc ADR (AUTL)’s stock chart: A technical perspective - US Post News
Stock Performance Spotlight: Autolus Therapeutics plc ADR (AUTL) Ends the Day at 3.63, Up by 4.31 - The Dwinnex
A look into Autolus Therapeutics plc ADR (AUTL)’s deeper side - SETE News
Are Autolus Therapeutics plc ADR (AUTL) shares a good deal now? - US Post News
Autolus Therapeutics plc ADR (AUTL)’s Market Momentum: Closing Strong at 3.73, Down -3.12 - The Dwinnex
Autolus Therapeutics (NASDAQ:AUTL) Shares Down 4.8% - MarketBeat
Autolus Therapeutics names new Chief Development Officer - Investing.com India
Autolus Therapeutics names new Chief Development Officer By Investing.com - Investing.com South Africa
Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Down 8.0% in August - Defense World
Autolus Therapeutics plc ADR (AUTL) looking to reclaim success with recent performance - SETE News
Autolus Therapeutics plc ADR (AUTL) Stock: Navigating a Year of Volatility - The InvestChronicle
Autolus Therapeutics plc (NASDAQ:AUTL) Shares Acquired by Daiwa Securities Group Inc. - Defense World
Autolus Therapeutics plc ADR (AUTL)’s stock price in review: A technical analysis - US Post News
Autolus Therapeutics Plc Adr Stock (AUTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):